Dencatistat
Appearance
| Clinical data | |
|---|---|
| Other names | STP938 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C24H27N7O5S |
| Molar mass | 525.58 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Dencatistat is an investigational new drug that is being evaluated by Step Pharma for the treatment of essential thrombocythemia, B-cell lymphoma, and T-cell lymphoma. It is a CTPS1 enzyme inhibitor.[1][2]
Clinical trials
[edit]Dencatistat is currently under clinical trials for lymphomas,[3] solid tumors,[4] and essential thrombocythemia.[5]
References
[edit]- ↑ "Dencatistat". AdisInsight. Springer Nature Switzerland AG. Retrieved 3 July 2026.
- ↑ Parker A (November 2020). "STP938, a Novel, Potent and Selective Inhibitor of CTP Synthase 1 (CTPS1) Is a Targeted Therapy Specifically Blocking De Novo Nucleotide Synthesis in Lymphomas and Leukemias". Blood. 136 (Supplement 1): 31. doi:10.1182/blood-2020-138436.
- ↑ "A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas". ClinicalTrials.gov. U.S. National Library of Medicine. Clinical trial record for NCT05463263. Retrieved 5 July 2026.
- ↑ "Study of STP938 (Dencatistat) in Advanced Solid Tumours". ClinicalTrials.gov. U.S. National Library of Medicine. Clinical trial record for NCT06297525. Retrieved 5 July 2026.
- ↑ "A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial". ClinicalTrials.gov. U.S. National Library of Medicine. Clinical trial record for NCT06786234. Retrieved 5 July 2026.